Driving innovation to advance allogeneic cell therapies through manufacturing platform development

“Our objective is to develop an end-to-end solution that enhances automation, ensures process closure, intensifies production where necessary, and ultimately simplifies the workflow.”

Abi Pinchbeck, Editor, Cell & Gene Therapy Insights, speaks to Jason Dowd, Global Lead Cell Therapy Platform Process, Bayer, to explore the latest advancements in allogeneic cell therapy platform development, automation strategies, and hurdles that industry must address to ensure broader patient access.

Please enter your email to access content Read now